All In Biotech

Drug Trial Radar · NCT05053152

Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

Last checked: Nov 20, 2026Latest source record: Aug 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 194 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

194

Planned (sponsor's estimate)

Start

Apr 20, 2022

Primary completion

Feb 1, 2029

Study completion Feb 1, 2034

Sponsor

Lead sponsor
NRG OncologyAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Cancer Institute (NCI)
First posted
Sep 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares the usual treatment of radiation therapy alone to using the study drug, relugolix, plus the usual radiation therapy in patients with castration-sensitive prostate cancer that has spread to limited other parts of the body (oligometastatic). Relugolix is in a class of medications called gonadotropin-releasing hormone (GnRH) receptor antagonists. It works by decreasing the amount of testosterone (a male hormone) produced by the body. It may stop the growth of cancer cells that need testosterone to grow. Radiation therapy uses high-energy x rays or protons to kill tumor cells. The addition of relugolix to the radiation may reduce the chance of oligometastatic prostate cancer spreading further.

Conditions

  • Oligometastatic Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Prostate Ductal Adenocarcinoma
  • Prostate Intraductal Carcinoma
  • Stage IVB Prostate Cancer AJCC v8

Interventions

  • Biospecimen CollectionProcedure

    Undergo urine and blood sample collection

  • Bone ScanProcedure

    Undergo bone scan

  • Computed TomographyProcedure

    Undergo CT and/or PET/CT

  • Fluciclovine F18Other

    Given fluciclovine F18

  • Magnetic Resonance ImagingProcedure

    Undergo MRI and/or PET/MRI

  • Placebo AdministrationDrug

    Given PO

  • Positron Emission TomographyProcedure

    Undergo PET/CT and/or PET/MRI

  • PSMA PET ScanProcedure

    Undergo PSMA PET/CT or PET/MRI

  • RelugolixDrug

    Given PO

  • Stereotactic Body Radiation TherapyRadiation

    Undergo SABR

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Radiological progression-free survival (rPFS)Time frame: Time from randomization to the occurrence of radiological progression detected by conventional imaging or death from any cause, assessed up to 5 years

Locations

245 sites in 2 countries. Site status is shown where the registry gives one.

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Tower Cancer Research Foundation

    Beverly Hills, California

  • Marin General Hospital

    Greenbrae, California

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Memorial Medical Center

    Modesto, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Sutter Medical Center Sacramento

    Sacramento, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Rocky Mountain Cancer Centers-Boulder

    Boulder, Colorado

  • UCHealth Memorial Hospital Central

    Colorado Springs, Colorado

  • Memorial Hospital North

    Colorado Springs, Colorado

  • AdventHealth Porter

    Denver, Colorado

  • Shaw Cancer Center

    Edwards, Colorado

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Cancer Care and Hematology-Fort Collins

    Fort Collins, Colorado

  • Banner North Colorado Medical Center

    Greeley, Colorado

  • UCHealth Greeley Hospital

    Greeley, Colorado

  • UCHealth Highlands Ranch Hospital

    Highlands Ranch, Colorado

  • AdventHealth Littleton

    Littleton, Colorado

  • Medical Center of the Rockies

    Loveland, Colorado

  • Banner North Colorado Medical Center - Loveland Campus

    Loveland, Colorado

  • AdventHealth Parker

    Parker, Colorado

  • Beebe South Coastal Health Campus

    Millville, Delaware

  • Helen F Graham Cancer Center

    Newark, Delaware

  • Medical Oncology Hematology Consultants PA

    Newark, Delaware

  • Beebe Health Campus

    Rehoboth Beach, Delaware

  • George Washington University Medical Center

    Washington D.C., District of Columbia

  • AdventHealth Altamonte

    Altamonte Springs, Florida

  • AdventHealth Celebration

    Celebration, Florida

  • Jupiter Medical Center

    Jupiter, Florida

  • GenesisCare USA - Lakewood Ranch

    Lakewood Rch, Florida

  • AdventHealth Orlando

    Orlando, Florida

  • GenesisCare USA - Plantation

    Plantation, Florida

  • Moffitt Cancer Center at SouthShore

    Ruskin, Florida

Showing 40 of 245 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.